C-LECTA
26.5.2021 10:19:08 CEST | Business Wire | Press release
c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, has submitted dossiers for two newly developed enzymes in the food sector. The evaluation by EFSA (European Food Safety Agency) and the EU Commission is based on the harmonized EU approval procedure for food improvement agents (food enzymes, food additives and food flavors). The enzyme dossiers submitted by c-LEcta for products in the target market of the food industry complement the company’s offering to its customers, who thus no longer have to worry separately about approvals for the use of the enzymes.
The two dossiers were submitted as part of an exclusive collaboration with an industry partner in the food sector for two food enzymes. Both enzymes are used to produce a natural sugar, for example, that can replace lactose, which has recently become unpopular with consumers, in industrially processed foods. With the help of the c-LEcta enzymes and the process developed by the cooperation partner, this sugar can be extracted from readily available sugar beets on a large scale.
“This is a typical case of enzymes making something entirely new and valuable possible. We are proud of this and, in cooperation with our partner, we are safeguarding this development result for the future. Thanks to our expertise in both new product development and regulatory matters, we can also provide our partners and customers with comprehensive support at this point,” explained Paula Pescador, responsible for enzyme dossiers at c-LEcta.
As part of the implementation of the FIAP (Food Improvement Agents Package), a new approval procedure was introduced for enzymes used in the production of food. This is intended to create a harmonized regulatory system for food enzymes throughout the European Union. Following evaluation by the European Food Safety Authority (EFSA), the EU Commission will draw up a positive list of enzymes approved in the EU for use in the food industry in the future. So-called enzyme dossiers have to be submitted for inclusion in this list, demonstrating the safety and technical necessity of the enzymes. The first publication of the new list is planned for 2023. From that date on, food manufacturers will only be allowed to use the enzymes listed. To provide customers with planning security, c-LEcta is therefore ensuring the necessary submission of enzyme dossiers so that the enzymes can already be included in the list when it is first published.
“The EU enzyme approval is of course a new process that everyone in the industry has to get used to. However, for us at c-LEcta, this is not a problem thanks to our in-house expertise and flexibility. On the other hand, the European positive list also offers us a simplification for the approval of new products for the food industry. Of course, we will continue to handle this in such a way that we submit these dossiers for all our products for the food industry. For us, this is a natural part of the service we provide to our customers,” concluded Dr. Marc Struhalla, founder and CEO of c-LEcta.
About c-LEcta
c-LEcta is a world-leading biotechnology company with a focus on enzyme engineering and application in regulated markets like the food and pharma industries. The company is based in Leipzig, Germany, and has established itself as a leading player in the realization of high-value biotech products, either in the form of in-house developments or in close cooperation with industry. The company currently employs more than 100 people.
c-LEcta delivers cost-efficient and sustainable production processes which open new markets and allow for better penetration of existing markets. The company is characterized by fast and efficient development of best-in-class biotech solutions and a rapid and successful market introduction and commercialization of the resulting products. This enables c-LEcta to leverage the unique potential of its core technologies. c-LEcta has a proven track record of more than ten successfully commercialized high-value industrial biotech products.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005470/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TREASoURcE Shows How Circular Economy Solutions Can Move Beyond Pilots Across Sectors and Regions19.5.2026 07:00:00 CEST | Press release
Across Europe, many circular economy solutions struggle to move beyond isolated pilots and into real-world deployment at scale. New approaches are needed that combine technical feasibility, market relevance and citizen engagement, while remaining adaptable to local contexts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518914041/en/ TREASoURcE addressed circular economy challenges across energy, plastics and biobased side streams, combining technical solutions with stakeholder and citizen engagement. The EU-funded TREASoURcE project provides evidence that systemic, citizen-engaged circular economy solutions can be developed, tested and prepared for replication across regions. Using a common regional approach, the project combined real-life demonstrations, cross-value chain collaboration and early consideration of transferability to translate circular economy concepts into practical solutions in the fields of energy, mat
Azafaros Strengthens Leadership Team With Appointment of Amy Sullivan as Chief Financial Officer19.5.2026 07:00:00 CEST | Press release
Experienced biotech finance leader with over 30 years’ experience in capital markets and strategyProven track record in fundraising, M&A and company transformationCompany is currently running two pivotal Phase 3 studies with nizubaglustat in GM1/ GM2 gangliosidoses and Niemann-Pick type C disease Azafaros, a private company building a portfolio to become a leader in Lysosomal Storage Disorders and focused on addressing neurological symptoms, today announced that Amy Sullivan has joined the company as Chief Financial Officer. Ms. Sullivan brings more than 30 years’ experience in the life sciences sector, with expertise in capital raising, corporate strategy and communications. She joins Azafaros from IO Biotech, where she served as Chief Financial Officer. “Amy is a highly accomplished financial leader with a strong track record of supporting growth-stage biotech companies,” said Stefano Portolano, Chief Executive Officer at Azafaros. “Her expertise in financing, strategic positioning a
Shufti Recognised as Dual Leader in Liminal's 2026 Age Verification and Age Estimation Indexes, with Exceptional Ratings Across Both Benchmarks19.5.2026 07:00:00 CEST | Press release
Liminal’s independent buyer-led research positions Shufti among the highest-scoring vendors on Product Execution, Strategy, and Market Presence, citing its risk-based age assurance, sub-second inference, and privacy-preserving on-device capabilities. Shufti has been named a Leader in both the Age Verification and Age Estimation categories of Liminal’s 2026 Index Report, receiving an Exceptional rating for Market Presence across both. Liminal, an actionable intelligence firm, evaluates identity verification vendors across Product Execution, Strategy, and Market Presence, assessing scalability, accuracy, fraud resistance, innovation, and user experience. Out of 189 vendors assessed in the Age Verification Index, only 17 achieved Leader status. Shufti was among them and exceeded the leadership threshold with a 64% Product Execution score and a 92% Strategy score. In Age Estimation, Shufti again ranked among 17 Leaders from 80 evaluated vendors, exceeding leadership thresholds across core
Tennis World Champion Carlos Alcaraz Becomes Global Brand Ambassador for Ant International19.5.2026 05:10:00 CEST | Press release
Global tennis icon Carlos Alcaraz has become the new Global Brand Ambassador for Ant International, a leading global digital payment, digitisation and financial technology provider, and its key brands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518952984/en/ (L-R) Ant International CEO Peng Yang and Carlos Alcaraz celebrate Global Brand Ambassador partnership This collaboration underscores Ant International’s commitment to enabling inclusive growth across global markets through a relentless pursuit of world-leading AI-powered payment and fintech solutions for businesses and individuals – a vision that mirrors the fierce energy and inspiration Carlos Alcaraz brings to every match. “Carlos is not only a sporting champion, but the very personification of the core values of tennis for fans worldwide: boundless ambition, unwavering dedication, scalpel precision in delivery, and sportsmanship both on and off the court,” sai
Hitachi Announces Strategic Partnership With Anthropic to Strengthen "Lumada 3.0" Through Frontier AI19.5.2026 02:00:00 CEST | Press release
Combining Hitachi’s 110+ years of domain expertise with frontier AI will advance safe real-world deployment of physical AI and strengthen customer AI transformation Deploying advanced AI across all business processes for approximately 290,000 employees to enhance productivity at scale Developing 100,000 AI professional talent and co-creating new HMAX solutions leveraging proven outcomes from Hitachi’s “Customer Zero” approach Establishing the “Frontier AI Deployment Center,” a global organization spanning North America, Europe, and Asia with an initial team of 100 experts Hitachi, Ltd. (TSE:6501, "Hitachi") today announced a strategic partnership with Anthropic PBC (“Anthropic”), a global leader in AI safety research and trusted AI models, to further strengthen the “Lumada 3.0” business model. As artificial intelligence evolves beyond cyberspace to directly influence real-world systems—otherwise known as physical AI—demand is rapidly growing for the safe and seamless deployment of AI i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
